I have been watching for some time as others in my field contribute to academic scholarship through blogs, postings and web-based commentary – and felt it was time to dive right in. There is some trepidation, as many who contribute to such writing are much more literate, organized and frankly just plain smarter than I am. Still, it felt like the time, and in this arena I had more to say. Immunocompromised patients make up anywhere from 2-3% of the entire US population (ref) – meaning nearly 65 million in the US are among this population. And as we expand immmunosuppressive therapies for patients, this population will grow. We have to be prepared for this shift.
Diving into a new blog can be a bit daunting – so good to come prepared with the right equipment.
I have been lucky to work with a number of phenomenal colleagues both at my institution and throughout the world – so hope that over time I can add more voices to this site. I can promise that I’ll do my best to be pithy, and that I’ll make mistakes. Regardless, I hope that this site becomes another way to call out excellent papers, to discuss new research in this complex field, and to talk about issues important to these patients.
Since this was one of my 2017 New Year’s resolutions, I will do my best to post at least once a week. I also apologize as I learn the tricks to the trade – so expect the site to look different over time, particularly as I become more comfortable with the software to change this site. I also ask for those with constructive commentary or feedback to let me know what you think – and for those antivaxxers or anti-science trolls – to please follow the storm troopers’ mantra and “Move along… Move along.”
At that I’ll get at it – hope you find it useful.
Published by Steven Pergam, MD, MPH, FIDSA
I am a clinical researcher at Fred Hutchinson Cancer Research Center in the Vaccine and Infectious Disease and Clinical Research Divisions, and faculty member at the University of Washington. I am interested in Infectious Diseases and Infection Prevention, with a focus on epidemiology of major pathogens, antibiotic resistance/usage, development of novel prevention strategies and patient/provider education among immunocompromised patient populations. I currently spend my research efforts on emerging pathogens in transplantation, respiratory viruses, fungal infections, and drug resistant bacterial infections. I currently serve as Director of Infection Prevention at the Seattle Cancer Care Alliance.
View all posts by Steven Pergam, MD, MPH, FIDSA